Using our novel bulk-hydrophilic biomaterial platform, we are developing superior venous access devices that address the key unmet need in the space—eliminating thrombotic risk. Our technology has several potential clinical applications. We are focused initially on developing and commercializing our lead product, the HydroPICC device, a peripherally inserted central catheter with superior material performance that has been shown in lab testing to significantly reduce the accumulation of platelets and in turn, the risk of thrombosis. Our robust pipeline includes midlines, dialysis catheter, and ports, all in various stages of development.
Our team has grown by more than 50 percent this year, in anticipation of commercial launch of the HydroPICC in early 2018. In our headquarters in Bedford, Massachusetts, our 7,100-square foot facility includes a state of the art lab and we will be expanding our footprint with an additional 4,000-square foot space for manufacturing.
After shadowing physicians in a Boston hospital and witnessing first-hand the delay in administering antibiotics to a severely ill patient due to infection risks from a catheter, Jim Biggins knew there had to be a better way. Leveraging his engineering expertise and experience with hydrogels, he applied those skills to found Access Vascular in 2015, with the goal of reinventing venous access. Jim has previously held engineering and new product development positions at Ocular Therapeutix, Boston Scientific and Medtronic. In these roles, he launched more than a dozen medical technology products from concept through commercialization. He also has been a partner in a venture creation group with responsibility for identifying opportunities, initiating companies and developing business strategies. Jim earned an M.B.A from Babson College and a B.S. in Plastics Engineering from the University of Massachusetts Lowell.
Michael Bassett joined Access Vascular in 2016 to oversee research and development, operations and quality activities. An R&D executive with more than 20 years of hydrogel biomaterial experience, he recently served as Director of Development at Ocular Therapeutix, where he co-invented and developed a drug delivery platform for commercialization. Michael also held a variety of product development, program manager and manufacturing positions with Confluent Surgical (Covidien), Anika Therapeutics, Spherics and Focal Inc. He earned a B.S. in Biology from Brown University. Michael is a member of the American Management Association, Parenteral Drug Association and Controlled Release Society. He holds a number of patents and has published several peer-reviewed papers on hydrogel technology.
Liz joined Access Vascular in the spring of 2017, in advance of the Company’s first anticipated 510K submission to FDA. In her role as Senior Regulatory Affairs and Quality Engineer, Liz will establish and lead execution of the company’s Quality Management System and develop the company’s regulatory and clinical strategy, including directing and coordinating US and OUS regulatory submissions. Liz previously worked at sister companies 480 Biomedical and Arsenal Medical, as well as Ocular Therapeutix, where she successfully led teams developing regulatory submissions in the US and UK. She earned a bachelor of science degree in Biomedical Engineering with a concentration in Bioinstrumentation from Worcester Polytechnic Institute.
Joseph P. Pellegrino, Jr. joined LeMaitre Vascular in 2005 and has served as Chief Financial Officer since 2007. Previously, Mr. Pellegrino served as an investment banking analyst at Lehman Brothers, as part of their mergers and acquisitions group.
Brent Ratz founded CardiAQ Valve Technologies with a cardiac surgeon to develop the first system for transcatheter mitral valve replacement (TMVR). Over the course of his nine-year tenure, he led the company’s successful financing and regulatory submissions. The company was acquired by Edwards Lifesciences in 2015.
Paul Sabin is principal at Fikst and has developed over two dozen products for alternative energy, medical, consumer, instrumentation, fitness and computer-peripheral markets. Mr. Sabin has an A.B. in Physics from Harvard University, an M.S. in Engineering Design from Tufts University, and an MBA from Olin School of Business at Babson College where he was an Olin Fellow and a Kauffman Fellow.
If you thrive in an environment where you can make a real difference in people’s lives and you will be challenged to be the best that you can be, we’d love to hear from you. Send your resume and cover letter to firstname.lastname@example.org.
Access Vascular is an equal opportunity employer.